Organic Chemical – Page 5

Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease

1 month ago talkbio0Tagged Antisense Oligonucleotides, curative potential, Hypertriglyceridemia, Ionis, Pancreatitis, Acute, Phase 3 Clinical Trials, RNA-targeted therapy, Severe (severity modifier), Submission, Triglycerides, TRYNGOLZA, United States Food and Drug Administration

Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy

FDA Extends Review Period for Rhythm Pharmaceuticals’ Imcivree (Setmelanotide) in Acquired Hypothalamic Obesity

1 month ago talkbio0Tagged Agonist, amendment, goal, Hypothalamic structure, Imcivree, MC4R protein, human, PDUFA, Phase 3 trial, review extension, Rhythm Pharmaceuticals, setmelanotide, United States Food and Drug Administration

Imcivree; Rhythm Pharmaceuticals; FDA; review extension; acquired hypothalamic obesity; setmelanotide; PDUFA goal date; Phase 3 trial; major amendment; MC4R agonist

Maximizing ROI with Educational Content for Healthcare Marketers: 2025 Trends and Strategies

1 month ago talkbio0Tagged Cell Differentiation process, Data Analytics, digital strategies, Educational content, Feeling content, Health Care Market, Market, Marketing, Metric (substance), Patient Engagement, Performance, personalization, POC, point-of-care, Region of interest:Presence or Identity:Point in time:*:Nominal

healthcare marketing; educational content; ROI; patient engagement; data analytics; AI personalization; point-of-care (POC) marketing; digital strategies; market differentiation; content performance metrics

Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

1 month ago talkbio0Tagged Adherence (attribute), Behavior, cardiometabolic, Contrave, craving control, Health, naltrexone-bupropion, non-incretin therapies, pharmaceutical innovation, Weight maintenance regimen

ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health

Dyne Therapeutics’ z-rostudirsen Shows Durable Efficacy, Supporting Positive Regulatory Outlook

2 months ago talkbio0Tagged Accelerated, Approved, Biological Markers, Clinical Trials, DELIVER (veterinary product), Dyne Therapeutics, Effectiveness, Functional improvement, Muscular Dystrophy, Duchenne, regulatory approval, z-rostudirsen

Dyne Therapeutics; z-rostudirsen; DELIVER trial; Duchenne muscular dystrophy (DMD); durable efficacy; regulatory approval; biomarkers; functional improvement; accelerated approval

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

2 months ago talkbio0Tagged Biktarvy, cell therapy sales, financial results, Gilead Sciences, HIV franchise, Livdelzi, Q3, Tecartus, Trodelvy, Veklury, Yescarta, Yeztugo

Gilead Sciences; cell therapy sales; Q3 2025 financial results; HIV franchise; Yescarta; Tecartus; Biktarvy; Yeztugo; Livdelzi; Trodelvy; Veklury

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

2 months ago talkbio0Tagged AH 001, AI-designed drug, Alopecia, Androgenetic Alopecia, AnHorn Medicines, Generative AI, Phase I Clinical Trials, protein degrader, Safety, tolerability

AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss

Merck & Co.’s Welireg Notches Wins in Kidney Cancer Combo Studies

2 months ago talkbio0Tagged adjuvant setting, Combined Modality Therapy, Disease-Free Survival, Keytruda, Lenvima, Malignant neoplasm of kidney, Phase 3 trials, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

2 months ago talkbio0Tagged calcium glucarate, Capital, Challenge, Changing, Cognitive function: planning, gains, Investments, Long-term, minimization, Private Equity, rates, Taxes

capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

2 months ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy